LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...
LUND, SE / ACCESSWIRE / November 20, 2023 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that...
Revolutionary Medical Device Companies Awarded with Prestigious Mid-Stage Grand Prize and Value Award at the MedTech Strategist Innovation SummitLOS ANGELES--(BUSINESS...
TORONTO, ON / ACCESSWIRE / November 17, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
The 10-year strategic collaboration builds on strong research foundations in medical imaging and expands the scope to advance the delivery...
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or...
Single treatment of bizaxofusp doubled mOS (14.5 months vs. 7.2 months) irrespective of IL4R expression (high or low) compared to...
Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual MeetingBRISBANE, Calif., Nov....
Press Release Stockholm, Sweden, November 17, 2023 Mendus AB (publ: IMMU.ST) announced today that the members of the Nomination Committee...
TAIPEI, Taiwan and SAN DIGEO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the...
Conference Call to be held on November 20th, 2023 at 5:00 PM ESTNEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE)...
- Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety...
Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer...
SPARKS, NV / ACCESSWIRE / November 16, 2023 / Ludwig Enterprises, Inc., the Genomics Language Company™, focused on the development...
BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure diabetesNew...
POLB 001 - a potential blockbuster immunomodulatorLONDON, UK / ACCESSWIRE / November 16, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or...
Partnership extends capability for trial imaging integration to Florence Healthcare's 18,000 activated clinical trial sites.ATLANTA, GA / ACCESSWIRE / November...
- Enrollment numbers rise to 239 in ongoing potentially pivotal study of Berubicin for treatment of GBM; Expected full enrollment...
TORONTO, ON / ACCESSWIRE / November 15, 2023 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare...
Dr. Chinn retired as a Rear Admiral of the United States NavyMINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation, a leading innovator in medical countermeasures,...